Hormone replacement therapy (HRT) shortage: switching to Femoston® (estradiol/dydrogesterone) from an alternative combination oral or transdermal HRT
Information for healthcare professionals only.
This Guidelines supplement has been commissioned and funded by Mylan and developed in partnership with Guidelines. The content on page 3 was commissioned by Mylan and Mylan has carried out full medical review and approval to ensure compliance. See page 2 for full disclaimer.
Information intended for healthcare professionals only.
Type 2 diabetes: an overview of the SIGN guideline on pharmacological management of glycaemic control
Production of this Guidelines supplement has been funded by an educational grant from Napp Pharmaceuticals Limited. The grant included an honorarium for the author. Napp Pharmaceuticals Limited has reviewed the supplement for technical accuracy and to ensure compliance with regulations. Napp Pharmaceuticals Limited has had no input into or ...